115 related articles for article (PubMed ID: 38007756)
1. Bio Informatics Analysis of the Relationship Between Mammalian Target of Rapamycin and Colorectal Cancer.
Han L; Lin L; Chen J; Yan B
Stud Health Technol Inform; 2023 Nov; 308():322-328. PubMed ID: 38007756
[TBL] [Abstract][Full Text] [Related]
2. lncRNA GAS5 inhibits malignant progression by regulating macroautophagy and forms a negative feedback regulatory loop with the miR‑34a/mTOR/SIRT1 pathway in colorectal cancer.
Zhang HG; Wang FJ; Wang Y; Zhao ZX; Qiao PF
Oncol Rep; 2021 Jan; 45(1):202-216. PubMed ID: 33416133
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
[TBL] [Abstract][Full Text] [Related]
4. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.
Alqurashi N; Gopalan V; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2089-96. PubMed ID: 23773481
[TBL] [Abstract][Full Text] [Related]
5. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer.
Yang M; Huang Q; Li C; Jiang Z; Sun J; Wang Z; Liang R; Li D; Li B; Zhao H
Front Immunol; 2021; 12():647540. PubMed ID: 33897695
[TBL] [Abstract][Full Text] [Related]
6. miR-212 and mTOR form a regulation loop to modulate autophagy in colorectal adenoma HT-29 cells.
Ji C; Ju S; Qiang J
Discov Med; 2018 Jun; 25(140):265-275. PubMed ID: 30021100
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression.
Qin A; Qian W
Int J Mol Med; 2018 Nov; 42(5):2503-2514. PubMed ID: 30226533
[TBL] [Abstract][Full Text] [Related]
8. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
[TBL] [Abstract][Full Text] [Related]
9. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR.
Li W; Chang J; Wang S; Liu X; Peng J; Huang D; Sun M; Chen Z; Zhang W; Guo W; Li J
Oncotarget; 2015 Sep; 6(27):24448-62. PubMed ID: 26259252
[TBL] [Abstract][Full Text] [Related]
10. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of aberrant mTOR activation in patients with stage II and III colorectal cancer.
Zhang TT; Zhu YQ; Cai HQ; Zheng JW; Hao JJ; Chang C; Cai Y; Wang MR; Liang JW; Zhang Y
Biomark Med; 2020 Aug; 14(12):1127-1137. PubMed ID: 32969244
[No Abstract] [Full Text] [Related]
12. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
13. mTOR pathway in colorectal cancer: an update.
Francipane MG; Lagasse E
Oncotarget; 2014 Jan; 5(1):49-66. PubMed ID: 24393708
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.
Iwaya T; Yokobori T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Sawada G; Takahashi Y; Ishibashi M; Wakabayashi G; Mori M; Mimori K
Carcinogenesis; 2012 Dec; 33(12):2391-7. PubMed ID: 22983984
[TBL] [Abstract][Full Text] [Related]
15. Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer.
Wang C; Aikemu B; Shao Y; Zhang S; Yang G; Hong H; Huang L; Jia H; Yang X; Zheng M; Sun J; Li J
BMC Cancer; 2022 Jul; 22(1):818. PubMed ID: 35883111
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated mTOR expression as a predictor of survival after liver resection for colorectal liver metastases.
Konishi T; Yoshidome H; Shida T; Furukawa K; Takayashiki T; Kuboki S; Takano S; Miyazaki M; Ohtsuka M
J Surg Oncol; 2021 Sep; 124(4):598-606. PubMed ID: 34061356
[TBL] [Abstract][Full Text] [Related]
17. Sex determining region Y-box 2 inhibits the proliferation of colorectal adenocarcinoma cells through the mTOR signaling pathway.
Liu H; Du L; Wen Z; Yang Y; Li J; Dong Z; Zheng G; Wang L; Zhang X; Wang C
Int J Mol Med; 2013 Jul; 32(1):59-66. PubMed ID: 23599173
[TBL] [Abstract][Full Text] [Related]
18. NAT1 is a critical prognostic biomarker and inhibits proliferation of colorectal cancer through modulation of PI3K/Akt/mTOR.
Cai J; Sun H; Chen L; Xie M; Zhuang J; Gao L; Wei XX
Future Oncol; 2021 Jul; 17(19):2489-2498. PubMed ID: 33906370
[TBL] [Abstract][Full Text] [Related]
19. [Expression of Rictor and mTOR in colorectal cancer and their clinical significance].
Wang LF; Chen HJ; Yu JL; Qi J; Lin XH; Zou ZW
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Mar; 36(3):396-400. PubMed ID: 27063170
[TBL] [Abstract][Full Text] [Related]
20. Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway.
Tian Y; Shen L; Li F; Yang J; Wan X; Ouyang M
J Cell Physiol; 2020 Jan; 235(1):442-453. PubMed ID: 31332784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
